Advertisement

American Society of Nephrology, Oct. 23-28

0
The Annual Meeting of the American Society of Nephrology, Kidney Week 2018 Kidney Week, the annual meeting of the American Society of Nephrology,...
Another hypertension drug is being recalled due to contamination that could pose a cancer risk

Second Hypertension Drug Recalled Due to Contamination

0
Some lots of irbesartan being recalled due to contamination with suspected carcinogen
Black women

Black, Low-Income Women May Not Report Barriers to Care

0
They are less likely to report barriers to early breast CA detection, less likely to get timely mammogram
There is a lack of convincing evidence for an association between statin use and non-cardiovascular disease outcomes

Link Between Statins, Non-CVD Outcomes Lacks Evidence

0
Review of observational studies, randomized trials shows absence of convincing evidence
A polygenic risk score can identify subsequent breast cancer risk among childhood survivors of cancer

Genetic Risk Score IDs Breast CA Risk in Female Child CA Survivors

0
Survivors in highest quintile of polygenic risk score have increased relative rate of breast cancer
A lack of understanding of terminology

Barriers to Prostate Cancer Research in Black Men Identified

0
Mistrust, lack of knowledge, unfavorable attitudes are barriers to genomic testing, study participation

American College of Surgeons, Oct. 22-26

0
The 103rd Annual American College of Surgeons Clinical Congress The annual meeting of the American College of Surgeons was held from Oct. 22...
Treatment with ketoprofen may improve the skin biology in lymphedema

Pilot Studies May Shed Light on How to Treat Lymphedema

0
Improvement in histopathology, skin thickness seen with ketoprofen in exploratory studies in humans
The risk for breast cancer recurrence can be extracted using disease-specific survival data

New Method Estimates Risk for Recurrence in Breast Cancer

0
Higher recurrence risk linked to older age, more advanced stage, HR-negative tumors
The use of angiotensin-converting enzyme inhibitors is associated with an increased risk for lung cancer compared with angiotensin receptor blockers

Angiotensin-Converting Enzyme Inhibitors May Up Lung CA Risk

0
Higher risk seen with ACEIs versus angiotensin receptor blockers; risk linked to duration of use